Boehringer Ingelheim to evaluate BI754091 with Amal's ATP128

Geneva, Switzerland-based biotech Amal Therapeutics has entered into a collaborative agreement with German family-owned pharma major Boehringer Ingelheim.

Amal will conduct an international Phase Ib clinical study, referred to as KISIMA-01, to evaluate the combination of its lead candidate, ATP128, with Boehringer’s anti-PD1 compound, BI754091, in microsatellite stable (MSS) patients with stage IV colorectal cancer. The KISIMA-01 study will begin in the second half of 2019.

Amal’s lead candidate, ATP128, is a chimeric recombinant protein designed using Amal’s proprietary vaccine technology platform, KISIMA. ATP128 comprises of a cell penetrating peptide (CPP) for antigen delivery, a TLR peptide agonist for self-adjuvanticity and a multiple antigenic domain (Mad). ATP128 is designed to treat colorectal cancer.